EDITORIAL
Published on 10 Jan 2023
Editorial: Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control
doi 10.3389/fonc.2022.1121120
- 1,031 views
- Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
- Research Topics
- Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control
Development of small molecule inhibitors and antibodies targeting AXL for tumor therapy and infectious disease control
8,867
Total downloads
29k
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 09 Mar 2022
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity
doi 10.3389/fonc.2022.821391
- 2,364 views
- 8 citations
REVIEW
Published on 03 Mar 2022
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
doi 10.3389/fonc.2022.811247
- 11,763 views
- 28 citations
REVIEW
Published on 28 Oct 2021
Immune Evasion Mechanism and AXL
doi 10.3389/fonc.2021.756225
- 7,934 views
- 29 citations
ORIGINAL RESEARCH
Published on 14 Oct 2021
G-749 Promotes Receptor Tyrosine Kinase TYRO3 Degradation and Induces Apoptosis in Both Colon Cancer Cell Lines and Xenograft Mouse Models
doi 10.3389/fphar.2021.730241
- 2,725 views
- 3 citations
Published in
Frontiers in Oncology
- Pharmacology of Anti-Cancer Drugs
Participating Journals
Frontiers in Pharmacology
- 4.4 impact factor
- 7.8 citescore
Impact
- 29kTopic views
- 20kArticle views
- 8,867Article downloads